Zaid Fadul, MD, FS, FAAFP, joins for part 2 to discuss what greater adoption of AI across health care ecosystems might mean for pharmacists, patients, and more.
Feature|Articles|May 1, 2026
Navigating Pharmacy’s AI Transformation and the Future of Patient Care
Author(s)Brian Nowosielski
With its capabilities improving rapidly in the health care space, technology and pharmacy experts discuss AI’s future place in pharmacy practice as further developments are released.
Advertisement
Advertisement
The pharmaceutical landscape is undergoing a radical shift as AWS launches Amazon Bio Discovery and Novo Nordisk partners with OpenAI, signaling a move toward AI-driven drug discovery that compresses decades of research into weeks.1,2
Related to this article
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.
Mark Ey, RPh, from NCPA, joins to discuss the opportunities for independent pharmacies within the ACCESS to Pharmacy Care Program.
Researchers say this net loss is unlikely to reverse without state and federal policy changes, including PBM reform.
Zaid Fadul, MD, FS, FAAFP, introduces the Nolla Derm app, what it might mean for pharmacists and their patients, and where AI prescribing is headed in the future.
Among a collection of patients across 15 pharmacies, researchers assessed acceptability and satisfaction with pharmacist-led clinical services.
For pharmacies competing with CVS and relying on Caremark to serve patients, the prospect of those businesses operating under separate ownership is significant.
The inquiry puts audit practices, including how pharmacies are selected for audit, proportionality, and pharmacy advocacy in focus.
Advertisement
Advertisement